The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 350.00
Bid: 346.00
Ask: 350.00
Change: 12.00 (3.55%)
Spread: 4.00 (1.156%)
Open: 348.00
High: 353.00
Low: 342.00
Prev. Close: 338.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS: Hutchmed revenue surges, Craven House's loss widens

Wed, 28th Feb 2024 17:31

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Says it swings to net income of USD100.8 million for 2023, from a USD360.8 million net loss in 2022. Revenue rises 97% to USD838.0 million from USD426.4 million, with Oncology/Immunology consolidated revenue more than tripling to high end of guidance, at USD528.6 million. Includes USD280 million of an upfront payment from deal with Takeda Pharmaceutical Co Ltd. Cash balance at December 31 is USD886.3 million, up from USD631.0 million one year prior. Company does not recommend a final dividend, unchanged from 2022. Guides for USD300 million to USD400 million in Oncology/Immunology consolidated revenue in 2024.

----------

Cykel AI PLC - London-based artificial technologies firm, founded in August 2023 - Posts operating loss and pretax loss of GBP1.4 million for the period from August 22 to November 30. Cash balance at November 30 is GBP1.6 million. Says management team continues to develop and refine its task operating system, pending the expected reverse takeover by London-based special purpose acquisition company Mustang Energy PLC agreed in January.

----------

Harmony Energy Income Trust PLC - Great Britain-focused investor in commercial-scale battery energy storage systems - Net asset value at October 31 is 115.40 pence per share, down from 120.55p one year previously. Reports adjusted NAV total return of positive 1.2% for the year to October 31, following a positive 23.4% return the year before. Pretax profit falls to GBP3.1 million from GBP48.4 million. Company increases total dividend for year to 8p per share from 2p, and says it is working hard to find solutions to its current challenges, including the "deteriorated" Great British battery energy storage systems or BESS market. Acknowledges however that due to "unexpectedly low" income its dividends were paid using VAT rebates, "which the board recognises is not what shareholders expect over the long term".

----------

Craven House Capital PLC - London-based investment fund with minority shareholding in four Swedish-managed eCommerce and pharmaceutical businesses - Pretax loss for six months to November 30 is USD114,000, widening from USD72,000 the prior year. Assets at period end total USD1.16 billion, down from USD6.43 billion one year prior. Loss per share widens to 2.95 US cents from 1.86 cents. Says investees remain at 'pre-revenue' stage of business development.

----------

Malin Corp PLC - Dublin-based investor in life sciences companies - Says cash at December 31 is EUR29.3 million, compared to USD173.9 million at the same time one year prior. This has grown to EUR34.5 million at February 26 due to receipt of a contingent milestone payment from a disposal to Sanofi SA in 2021. Estimated intrinsic equity value was EUR6.56 per share at December 31 and EUR7.91 at February 26. Company says it returns EUR140.7 million of capital to shareholders throughout 2023 with a tender offer and on-market buybacks. Company also says Executive Chair Liam Daniel's role will revert to non-executive chair from Thursday.

----------

AIQ Ltd - company focused on acquiring and developing e-commerce sector businesses - Revenue for the year to October 31 falls to GBP207,209 from GBP496,296 annually. Pretax loss widens to GBP503,198 from GBP336,731. Says these results reflect challenging environment for non-fungible tokens and other blockchain technology-based products. Cash balance at October 31 is GBP135,445, down from GBP636,459 one year prior. Company says it continues to closely monitor its cash position and "is keeping all its strategic options open should the markets not turn favourable in the near-term".

----------

Renewables Infrastructure Group Ltd - investor in wind, solar and battery storage projects in Europe, advised by InfraRed Capital Partners Ltd - NAV per share at December 31 is 127.7p, down from 134.6p one year prior. Says reduction was driven by lower power price forwards and higher valuation discount rates. Says portfolio revenue for 2023 was GBP793 million, down from GBP838 million in 2022. Portfolio earnings before interest, tax, depreciation and amortisation falls to GBP610 million from GBP677 million. Dividend for 2023 totals 7.18p per share, and company is targeting a payout of 7.47p per share for 2024. Adds that the macroeconomic environment looks more "benign" this year.

----------

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
15 Jul 2022 13:20

IN BRIEF: Hutchmed starts phase I trial of HMPL-A83

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Begins phase I trial of HMPL-A83 for patients with advanced malignant neoplasms, in China. HMPL-A83 is an investigational novel IgG4-type humanized anti-CD47 monoclonal antibody. Malignant neoplasms are cancerous tumours. It has "significant" potential to be used as a combination therapy with Hutchmed's existing portfolio, the firm says.

Read more
13 Jul 2022 09:35

IN BRIEF: Hutchmed presents solid results from lung cancer study

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Presents positive results from the Savannah phase two trial of Hutchmed and AstraZeneca PLC's savolitinib in combination with Astra's osimertinib in epidermal growth factor receptor-mutated non-small cell lung cancer patients.

Read more
6 Jul 2022 10:37

AIM WINNERS & LOSERS: Hutchmed down amid China Covid woes; Parkmead up

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
6 Jul 2022 09:25

Hutchmed phase I trial for IMG-007 doses first patient

(Alliance News) - Hutchmed China Ltd on Wednesday announced the first patient has been dosed for its phase I trial for IMG-007.

Read more
1 Jun 2022 10:07

IN BRIEF: Hutchmed China wins cancer drug Tazverik approval in Hainan

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Receives approval for Tazverik from the Health Commission & Medical Products Administration of the Hainan province in China. The approval is for use in the Hainan pilot zone under the Clinically Urgently Needed Imported Drugs scheme, for the treatment of certain patients with epithelioid sarcoma and follicular lymphoma.

Read more
3 May 2022 12:14

LONDON MARKET MIDDAY: Stocks down as aggressive US Fed rate hike looms

(Alliance News) - Stock prices in London were lower at midday on Tuesday following the long bank holiday weekend in the UK, as markets globally prepare for a sharp US interest rate hike and similar moves by other central banks as they struggle to control inflation.

Read more
3 May 2022 11:29

AIM WINNERS & LOSERS: Hutchmed sinks on US FDA drug rejection

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
3 May 2022 11:25

IN BRIEF: US FDA says Hutchmed's pancreatic drug needs more testing

Hutchmed (China) Ltd - Hong Kong-based biopharmaceuticals - The US Food & Drug Administration has rejected Hutchmed's surufatinib for treatment of pancreatic neuroendocrine tumours. In a complete response letter, the FDA says the current data package, based on two positive phase three trials in China and one bridging study in the US, does not support an approval in the US "at this time". The FDA said a multi-regional clinical trial of surufatinib required for US approval. Surufatinib was approved in China for the treatment of pNETs and extra-pancreatic neuroendocrine tumours in June 2021 and December 2020, respectively. Chief Executive Officer & Chief Scientific Officer Weiguo Su comments: "Although this decision from the FDA is disappointing, we remain confident about the clinical value of surufatinib for NET patients and committed to making surufatinib available to patients globally. We look forward to working with the agency to evaluate its feedback."

Read more
3 May 2022 08:57

LONDON MARKET OPEN: BP rises despite taking hit from Rosneft exit

(Alliance News) - Stock prices in London opened lower on Tuesday following the long bank holiday weekend, with BP shares rising as the oil major planned to return cash to shareholders amid calls by some UK politicians for a windfall profit tax on energy companies.

Read more
3 May 2022 07:53

LONDON MARKET PRE-OPEN: BP swings to quarterly loss after Rosneft exit

(Alliance News) - Stock prices in London are seen opening lower on Tuesday, after the long bank holiday weekend in the UK, as concerns rise over aggressive monetary policy tightening by the US Federal Reserve.

Read more
25 Apr 2022 10:45

AIM WINNERS & LOSERS: musicMagpie sells on new platform; Hutchmed down

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
20 Apr 2022 16:05

UK shareholder meetings calendar - next 7 days

Thursday 21 April 
Alliance Trust PLCAGM
Ibstock PLCAGM
Journeo PLCAGM
Relx PLCAGM
STV Group PLCAGM
Ruffer Investment Co LtdEGM re share issue
Friday 22 April 
Bellevue Healthcare Trust PLCAGM
Faron Pharmaceuticals LtdAGM
Murray International Trust PLCAGM
Monday 25 April 
Belluscura PLCAGM
Capital Gearing Trust PLCGM re non pre-emptive share issue
Cloudbreak Discovery PLCGM re Crescita equity drawdown agreement
Hikma Pharmaceuticals PLCAGM
JPMorgan US Smaller Cos Investment Trust PLCAGM
Polymetal International PLCAGM
Symphony International Holdings LtdAGM
Tuesday 26 April 
Aquis Exchange PLCAGM
Elementis PLCAGM
GlobalData PLCAGM
Oriole Resources PLCAGM
RPS Group PLCAGM
SigmaRoc PLCAGM
Taylor Wimpey PLCAGM
Tissue Regenix Group PLCAGM
Wednesday 27 April 
Drax Group PLCAGM
EP Global Opportunities Trust PLCAGM
Global Invacom Group LtdAGM
Hutchmed (China) LtdAGM
London Stock Exchange Group PLCAGM
McKay Securities PLCGM re Workspace offer
Nichols PLCAGM
Persimmon PLCAGM
Primary Health Properties PLCAGM
VH Global Sustainable Energy Opportunities PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
31 Mar 2022 10:43

IN BRIEF: Hutchmed China named by SEC, might delist Nasdaq shares

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - US Securities & Exchange Commission identifies Hutchmed China under the new Holding Foreign Companies Accountable Act, which identifies public companies who have used auditors from overseas or auditors who are unable to be investigated completely. The new regulation has no impact on business operations, Hutchmed says.

Read more
31 Mar 2022 10:04

Hutchmed China confident after being added to SEC list

(Sharecast News) - Hutchmed China updated the market on its status under the United States 'Holding Foreign Companies Accountable Act' on Thursday.

Read more
11 Mar 2022 11:15

AIM WINNERS & LOSERS: Omega Diagnostics Visitect not available in UK

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.